Keras/TensorFlow in Drug Design for Immunity Disorders
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241915009 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Paulina Dragan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Chemistry, University of Warsaw, Pasteura 1, 02-903 Warsaw, Poland. Hauptthemen laut MEDLINE: Chemokines, Cytokines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre in Poland, Poland’s high-performance Infrastructure PLGrid (HPC Centers: ACK Cyfronet AGH).
Abstract (Originalsprache)
Homeostasis of the host immune system is regulated by white blood cells with a variety of cell surface receptors for cytokines. Chemotactic cytokines (chemokines) activate their receptors to evoke the chemotaxis of immune cells in homeostatic migrations or inflammatory conditions towards inflamed tissue or pathogens. Dysregulation of the immune system leading to disorders such as allergies, autoimmune diseases, or cancer requires efficient, fast-acting drugs to minimize the long-term effects of chronic inflammation. Here, we performed structure-based virtual screening (SBVS) assisted by the Keras/TensorFlow neural network (NN) to find novel compound scaffolds acting on three chemokine receptors: CCR2, CCR3, and one CXC receptor, CXCR3. Keras/TensorFlow NN was used here not as a typically used binary classifier but as an efficient multi-class classifier that can discard not only inactive compounds but also low- or medium-activity compounds. Several compounds proposed by SBVS and NN were tested in 100 ns all-atom molecular dynamics simulations to confirm their binding affinity. To improve the basic binding affinity of the compounds, new chemical modifications were proposed. The modified compounds were compared with known antagonists of these three chemokine receptors. Known CXCR3 compounds were among the top predicted compounds; thus, the benefits of using Keras/TensorFlow in drug discovery have been shown in addition to structure-based approaches. Furthermore, we showed that Keras/TensorFlow NN can accurately predict the receptor subtype selectivity of compounds, for which SBVS often fails. We cross-tested chemokine receptor datasets retrieved from ChEMBL and curated datasets for cannabinoid receptors. The NN model trained on the cannabinoid receptor datasets retrieved from ChEMBL was the most accurate in the receptor subtype selectivity prediction. Among NN models trained on the chemokine receptor datasets, the CXCR3 model showed the highest accuracy in differentiating the receptor subtype for a given compound dataset.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Chemistry, University of Warsaw, Pasteura 1, 02-903 Warsaw, Poland.
- Department of Life and Environmental Science, Food Toxicology Unit, University of Cagliari, University Campus of Monserrato, SS 554, 09042 Cagliari, Italy.
ORCID-Profile: Paulina Dragan, Alessandro Atzei, Dorota Latek
Förderung
- National Science Centre in Poland
- Poland’s high-performance Infrastructure PLGrid (HPC Centers: ACK Cyfronet AGH)
Zitieren
APA
Dragan, P., Joshi, K., Atzei, A., & Latek, D. (2023). Keras/TensorFlow in Drug Design for Immunity Disorders. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241915009
Vancouver
Dragan P, Joshi K, Atzei A, Latek D. Keras/TensorFlow in Drug Design for Immunity Disorders. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241915009
BibTeX
@article{Dragan2023,
author = {Dragan, Paulina and Joshi, Kavita and Atzei, Alessandro and Latek, Dorota},
title = {Keras/TensorFlow in Drug Design for Immunity Disorders},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241915009}
}
EUVIMED